GE HealthCare Technologies Inc. Common Stock Q2 2026 Earnings Recap

Shares rose 9.1% following GE Healthcare’s second quarter report, driven by stronger-than-expected order growth and product innovation momentum, particularly in pharmaceutical diagnostics and advanced imaging. Despite challenges in Patient Care Solutions (PCS), the market rewarded progress in backlog expansion and recurring revenue streams.

Key Takeaways

• Orders grew 11% with record backlog increasing $2.6 billion year-over-year and a book-to-bill ratio of 1.15x, underscoring strong demand across segments and geographies.
• Pharmaceutical diagnostics and advanced imaging led revenue growth, including robust double-digit growth in Vizamyl amyloid PET imaging and expansion in radiopharmaceuticals.
• Patient Care Solutions remained a weak spot with ongoing revenue and margin pressure, prompting strategic review including potential sale or restructuring options.
• New AI-enabled product launches and software upgrades, such as True Definition DL for CT imaging with subscription revenue models, are enhancing competitive positioning.
• Operational initiatives focused on commercial realignment and supply chain improvements aim to convert backlog into revenue and improve PCS performance in the second half.